

TC

JUN. 7. 2004 4:46PM

JCWSCS 08 JUN 2004

MBS&S 919 854-1401

NO. 1527 P. 1

MYERS BIGEL SIBLEY & SAJOVEC
Patent Attorneys
4140 Parklake Avenue, Suite 600, Raleigh, NC 27612
P.O. Box 37428, Raleigh, NC 27627
Telephone 919-854-1400
Facsimile 919-854-1401

**TELECOPIER TRANSMISSION
COVER SHEET**

Date: June 7, 2004

File Number: 5573-115IP7CT7

Telecopier No.: 703/746-9195

To: Filing Receipt Corrections
Office of Initial Patent Examination
U.S. Patent and Trademark Office

From: Jarrett K. Abramson

Return fax to: Katie

Number of Pages (including cover page): 4

If there is a problem with this transmission, please call (919) 854-1400. Our fax number is (919) 854-1401.

In re: Whittle *et al.*
Serial No.: 10/769,021
Filed: January 30, 2004
For: *Pharmaceutical Formulations*

Confirmation No.: 9712
Group Art Unit: 1614

Confidentiality Note

The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby prohibited. If you have received this telecopy in error, please immediately notify us by telephone and return the original message to us at the address above via the United States Postal Service. THANK YOU.

Attorney Docket No. 5573-1151P7CT7

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Whittle *et al.*
Serial No.: 10/769,021
Filed: January 30, 2004
For: *Pharmaceutical Formulations*

Confirmation No.: 9712
Group Art Unit: 1614

Date: June 7, 2004
Via Facsimile 703-746-9195

Office of Initial Patent Examination's Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT


Sir:

In reviewing the Official Filing Receipt (copy attached) for the above referenced application, Applicants note that the invention title incorrectly appears as "*Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same*".

Applicants respectfully request that the invention title be corrected to read "*Pharmaceutical Formulations*", as previously requested in the Preliminary Amendment submitted on January 30, 2004. Additionally, Applicants request that a corrected Filing Receipt be issued.


If any extension of time for the accompanying response or submission is required, Applicant requests that this be considered a petition therefor. The Commissioner is hereby authorized to charge any additional fee, which may be required, or credit any refund, to our Deposit Account No. 50-0220.

Respectfully submitted,


Jarett K. Abramson
Registration No. 47,376

USPTO Customer No. 20792
Myers Bigel Sibley & Sajovec
Post Office Box 37428
Raleigh, North Carolina 27627
Telephone: 919/854-1400
Facsimile: 919/854-1401

Certificate of Mailing under 37 CFR 1.8
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 7, 2004.


Katie A. Chung




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/769,021	02/02/2004	1614	856	5573-115IP7CT7		20	4

20792
 MYERS BIGEL SIBLEY & SAJOVEC
 PO BOX 37428
 RALEIGH, NC 27627



CONFIRMATION NO. 9712

FILING RECEIPT



OC000000012502208

Date Mailed: 05/03/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Robert R. Whittle, Wilmington, NC;
 Frederick D. Sancilio, Wilmington, NC;
 Grayson Walker Stowell, Wilmington, NC;
 Douglas John Jenkins, Wilmington, NC;
 Linda B. Whittall, Wilmington, NC;

Domestic Priority data as claimed by applicant

This application is a CON of 10/434,259 05/08/2003 PAT 6,706,737
 which is a CON of 10/189,659 07/03/2002 PAT 6,667,321
 which is a CON of 10/057,659 01/25/2002 PAT 6,444,689
 which is a CON of 09/645,145 08/24/2000 PAT 6,369,087
 which is a CIP of 09/519,976 03/07/2000 PAT 6,262,085
 which claims benefit of 60/150,878 08/28/1999

Foreign Applications

If Required, Foreign Filing License Granted: 04/30/2004

Projected Publication Date: 08/12/2004

Non-Publication Request: No

05-05-04 A09:21 IN

Early Publication Request: No

Title

Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).